2016, Number 1
Otorrinolaringología 2016; 61 (1)
Detection by distortion product otoacustic emissions of cochlear toxicity of amikacin in pediatric patients with neutropenic fever
Villafuerte-Aguilar F, Cárdenas-Velásquez MI, Peñaloza-González JG
Full text
Language: Spanish
References: 11
Page: 1-6
PDF size: 526.69 Kb.
ABSTRACT
Background: The distortion product otoacoustic emissions support us in drugs monitoring such as aminoglycosides which have high cochlear toxicity.Objective: To identify the role of distortion product otoacoustic emissions of the amikacin’s cochlear toxicity in early diagnosis, in patients with neutropenic fever, attended at the department of pediatric oncology in Hospital Juarez de Mexico.
Material and Method: A descriptive, observational, longitudinal, non-experimental, prospective study for one year, from October 2012 to October 2013, was made in 10 pediatric patients, indiscriminate sex, diagnosed with neutropenic fever, hospitalized in the pediatric oncology service in Hospital Juarez de Mexico, newly diagnosed with an oncology disease, with at least seven days of treatment with amikacin (15 mg/kg/day) twice a day; distortion product otoacoustic emissions were performed during the seven days of treatment.
Results: The aminoglycoside amikacin affected 6 of 10 patients analyzed. In patients with neutropenic fever, the amikacin’s cochlear toxicity increased 60%. Amikacin’s toxicity has predilection for female patients, being this one of bilateral predominance. The most affected age group by amikacin’s toxicity ranged from 10 to 16 years .
Conclusions: The distortion product otoacoustic emissions may be useful in monitoring amikacin’s toxicity. The amikacin’s risk-benefit must be reassessed due to the high risk of cochlear toxicity.
REFERENCES